RVPMEDIUM SIGNALOPERATIONAL10-K

RVP experienced significant operational challenges from widespread tariff volatility throughout 2025, while showing signs of recovery with improved gross margins and reduced operating losses despite declining cash position.

The company faced unprecedented tariff uncertainty in 2025 as rates "fluctuated greatly" beyond the specific China tariffs, creating unpredictable import costs that materially impacted business operations. However, RVP appears to be adapting, achieving positive gross profit margins after previous losses and reducing operating cash flow deficits by 39%, suggesting improving operational efficiency despite external headwinds.

Comparing 2026-03-27 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

RVP showed mixed but generally improving operational performance with revenue growing 15.8% to $38.3M and a dramatic turnaround in gross profit from -$1.0M to +$47K. However, the company's balance sheet weakened with cash declining 38.9% to $2.6M, total assets shrinking 11.3%, and stockholders' equity falling 14.7% to $74.4M, likely reflecting the impact of increased share buybacks ($7.6M vs $5.3M) and ongoing operational challenges. The combination of revenue growth, margin recovery, and reduced operating losses suggests stabilization, but the deteriorating cash position and asset base warrant monitoring.

FINANCIAL STATEMENT CHANGES
Gross Profit
P&L
+104.6%
-$1.0M$47K

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Capital Expenditure
Cash Flow
+68.8%
$853K$1.4M

Capital expenditure jumped 68.8% — major investment cycle underway; assess returns on deployment.

Share Buybacks
Cash Flow
+44.5%
$5.3M$7.6M

Share repurchases increased 44.5% — management returning capital, signals confidence in intrinsic value.

Cash & Equivalents
Balance Sheet
-38.9%
$4.2M$2.6M

Cash declined 38.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
+38.9%
-$11.6M-$7.1M

Operating cash flow surged 38.9% — exceptional cash generation, highest quality earnings signal.

Total Debt
Balance Sheet
-27.3%
$1.2M$896K

Debt reduced 27.3% — deleveraging strengthens balance sheet and reduces financial risk.

Revenue
P&L
+15.8%
$33.0M$38.3M

Revenue growing 15.8% — solid top-line momentum, watch margins for quality of growth.

Stockholders Equity
Balance Sheet
-14.7%
$87.2M$74.4M

Equity decreased 14.7% — buybacks or losses reducing book value, monitor solvency ratios.

Current Assets
Balance Sheet
-13.9%
$73.3M$63.1M

Current assets declined 13.9% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-11.3%
$160.7M$142.6M

Total assets contracted 11.3% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-28
ADDED
As of March 9, 2026, there were 29,937,159 shares of our Common Stock outstanding, excluding treasury shares.
Beginning in early 2025 and throughout much of the year, additional widespread tariffs were imposed on most products imported into the U.S.
citing authority under the International Emergency Economic Powers Act ( IEEPA ).
Those tariffs were in addition to the Section 301 tariffs which existed at the time.
Throughout 2025, the prevailing tariff rates on various products and certain countries of origin, including many of our products, fluctuated greatly.
+7 more — sign up free →
REMOVED
As of March 10, 2025, there were 29,937,159 shares of our Common Stock outstanding, excluding treasury shares.
Our syringes are well-suited for administering vaccinations and our revenues materially increased in 2020-2021 due to COVID-19 vaccination demand.
government for vaccinations wound down in the first quarter of 2022, although international vaccination demand positively and materially impacted sales throughout 2022 and the first quarter of 2023.
In September 2024, a new 100% tariff on syringes and needles imported from China became effective.
Additionally, effective February 4th and March 4th of 2025, tariffs on Chinese imports were increased by an aggregate total of 20%.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →